Dr Reddys Laboratories gains post launching Dexmedetomidine Hydrochloride in US market

Dr Reddy’s Laboratories, an Indian multinational pharmaceutical company, announced the launch of Dexmedetomidine Hydrochloride on Friday. Reacting to the news, its share gained as much as 2 per cent on BSE.

The pharmaceutical company launched Dexmedetomidine Hydrochloride in 0.9 per cent Sodium Chloride injection. It is a therapeutic equivalent generic version of Precedex (Dexmedetomidine Hydrochloride) in 0.9 per cent Sodium Chloride injection, which has been approved by United States Food & Drug Administration (USFDA).

Dr Reddy’s has launched the injection at an affordable price, making it readily available for patients. The company’s capacity to adequately supply Dexmedetomidine is significant as it's on the FDA’s drug shortage list.

The company’s Dexmedetomidine Hydrochloride in 0.9 per cent Sodium Chloride injection is offered in 200 mcg/50 ml and 400 mcg/100 ml in 50 ml and 100 ml with containers, which are intended for single-dose only.

According to IQVIA Health, Precedex in 0.9 per cent Sodium Chloride injection brand and the generic market had US sales of approximately USD 210 million MAT for the most recent twelve months ending in June 2020.

At 2.42 pm, the share was trading at Rs 5,090.95 with gains of 1.31 per cent on BSE.